Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Coe

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Neuropharmacology|December 13, 2006
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aidH Rollema, L K Chambers, J W Coe, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2005
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessationJotham W Coe, Paige R Brooks, Michael C Wirtz, et al.
Journal of Medicinal Chemistry|December 17, 2016
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and SkinPeter Jones, R Ian Storer, Yogesh A Sabnis, et al.
Journal of Medicinal Chemistry|November 14, 2018
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent InhibitorsAgustin Casimiro-Garcia, John I Trujillo, Felix Vajdos, et al.
Plos One|October 8, 2013
Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in miceDavid C Pryde, Lyn H Jones, David P Gervais, et al.
Journal of Medicinal Chemistry|May 13, 2005
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessationJotham W Coe, Paige R Brooks, Michael G Vetelino, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2010
A novel series of [3.2.1] azabicyclic biaryl ethers as alpha3beta4 and alpha6/4beta4 nicotinic receptor agonistsJohn A Lowe, Shari L DeNinno, Jotham W Coe, et al.
Journal of Medicinal Chemistry|January 2, 2010
Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition modelsChristopher J O'Donnell, Bruce N Rogers, Brian S Bronk, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Neuropharmacology|December 13, 2006
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aidH Rollema, L K Chambers, J W Coe, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2005
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessationJotham W Coe, Paige R Brooks, Michael C Wirtz, et al.
Journal of Medicinal Chemistry|December 17, 2016
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and SkinPeter Jones, R Ian Storer, Yogesh A Sabnis, et al.
Journal of Medicinal Chemistry|November 14, 2018
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent InhibitorsAgustin Casimiro-Garcia, John I Trujillo, Felix Vajdos, et al.
Plos One|October 8, 2013
Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in miceDavid C Pryde, Lyn H Jones, David P Gervais, et al.
Journal of Medicinal Chemistry|May 13, 2005
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessationJotham W Coe, Paige R Brooks, Michael G Vetelino, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2010
A novel series of [3.2.1] azabicyclic biaryl ethers as alpha3beta4 and alpha6/4beta4 nicotinic receptor agonistsJohn A Lowe, Shari L DeNinno, Jotham W Coe, et al.
Journal of Medicinal Chemistry|January 2, 2010
Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition modelsChristopher J O'Donnell, Bruce N Rogers, Brian S Bronk, et al.
Pageof 4